Abstract
Twenty-four symptomatic patients with advanced non-small cell lung cancer (NSCLC) were treated with cisplatin-based chemotherapy (mitomycin-C 8 mg m-2 q 6 weeks, vinblastine 6 mg m-2 q 3 weeks, cisplatin 50 mg m-2 q 3 weeks). Patients were assessed for symptom relief as well as for objective response. Although only five patients achieved an objective response (21%), 18 patients (75%) reported a complete disappearance or good improvement in at least one of their tumour-related symptoms. The overall symptomatic response rate was 67% with 16 patients feeling better or much better on treatment. The toxicity of treatment (primarily myelosuppression and nausea and vomiting) was mild and hair loss was minimal. The high incidence of symptomatic relief seen in this study, even in the absence of objective response, suggests that moderate dose chemotherapy may have a role in the palliation of NSCLC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hardy, J., Noble, T. & Smith, I. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer 60, 764–766 (1989). https://doi.org/10.1038/bjc.1989.355
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.355
This article is cited by
-
Gefitinib (ZD1839, Iressaâ„¢) as palliative treatment in recurrent or metastatic head and neck cancer
British Journal of Cancer (2006)
-
Combination chemotherapy in the treatment of inoperable non-small cell lung cancer
Irish Journal of Medical Science (2002)
-
The role of new agents in advanced non—small–cell lung carcinoma
Current Oncology Reports (2000)
-
Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C
Cancer Chemotherapy and Pharmacology (1995)